Dr. Choyke on Developments for the Screening of Prostate Cancer

Peter Choyke, MD, FACR
Published: Monday, Aug 14, 2017



Peter Choyke, MD, FACR, chief of Molecular Imaging Program, National Cancer Institute, discusses developments being made in screening for patients with prostate cancer.

According to Choyke, the rise of genomics in prostate cancer is an important development. However, genomic testing is not likely to be able to stand on its own without imaging. Imaging provides better sampling of the tumor, which leads to more accurate genomics, states Choyke.
 


Peter Choyke, MD, FACR, chief of Molecular Imaging Program, National Cancer Institute, discusses developments being made in screening for patients with prostate cancer.

According to Choyke, the rise of genomics in prostate cancer is an important development. However, genomic testing is not likely to be able to stand on its own without imaging. Imaging provides better sampling of the tumor, which leads to more accurate genomics, states Choyke.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x